USA - NASDAQ:SNY - US80105N1054 - ADR
The current stock price of SNY is 50.58 USD. In the past month the price decreased by -0.63%. In the past year, price decreased by -5.05%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.24 | 816.66B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.86B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.56 | 255.48B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 239.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.81 | 219.77B | ||
| MRK | MERCK & CO. INC. | 9.87 | 214.76B | ||
| PFE | PFIZER INC | 7.27 | 140.15B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.77B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48 | 42.45B | ||
| HLN | HALEON PLC-ADR | 19.31 | 41.28B |
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008 FR
CEO: Paul Hudson
Employees: 84587
Phone: 33153774000
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
The current stock price of SNY is 50.58 USD. The price decreased by -0.71% in the last trading session.
SANOFI-ADR (SNY) has a dividend yield of 4.45%. The yearly dividend amount is currently 2.19.
SNY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
SNY stock is listed on the Nasdaq exchange.
SANOFI-ADR (SNY) operates in the Health Care sector and the Pharmaceuticals industry.
SANOFI-ADR (SNY) has a market capitalization of 123.27B USD. This makes SNY a Large Cap stock.
ChartMill assigns a technical rating of 6 / 10 to SNY. When comparing the yearly performance of all stocks, SNY turns out to be only a medium performer in the overall market: it outperformed 42.59% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to SNY. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months SNY reported a non-GAAP Earnings per Share(EPS) of 4.39. The EPS decreased by -5.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.35% | ||
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| Debt/Equity | 0.21 |
29 analysts have analysed SNY and the average price target is 62.28 USD. This implies a price increase of 23.14% is expected in the next year compared to the current price of 50.58.
For the next year, analysts expect an EPS growth of 4.12% and a revenue growth -0.42% for SNY